Featured Story | By Nick Paul Taylor AstraZeneca has extended its drug delivery collaboration with Aptamer Group. The revised deal sets AstraZeneca up to build on research into the use of aptamer molecules to target renal cells. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor The FDA has granted tentative approval of the first generic version of AstraZeneca’s blockbuster drug Symbicort. Viatris and Kindeva Drug Delivery secured the tentative approval but still face a patent barrier to launch, with AstraZeneca prevailing in a court case last week. read more By Nick Paul Taylor ImmunityBio and NantKwest have begun dosing participants with subcutaneous, sublingual and oral COVID-19 vaccine candidates. The trials are designed to determine which combination of routes of administration holds the most potential. read more By Nick Paul Taylor Sorrento Therapeutics has moved to buy a delayed burst release formulation of low-dose naltrexone from Aardvark Therapeutics. The formulation is set to move into a phase 2 fibromyalgia clinical trial this year. read more By Conor Hale,Ben Adams,Amirah Al Idrus,Angus Liu Each member of this year’s class of Fierce 15 stands out in a different way, but they all overcame a year of unforgettable obstacles, making each of their successes much more significant. read more Resources Sponsored By: Almac Clinical Technologies This industry report reveals qualitative and quantitative candid insight from clinical development insiders and their views on current clinical trial challenges faced amidst uncertainty. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: AmerisourceBergen Corporation Unlock product potential by making the most of your commercialization investments. Sponsored By: Acorn AI Unlock competitive advantage with AI and advanced analytics. Sponsored By: EVERSANA Mature brands lost billions in revenue and value during COVID, but with the right strategy, pharma can rebound and reignite revenue. Learn How. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Thermo Fisher Scientific Involved in vaccine development? Check out this timely infographic detailing the history of vaccines, key development milestones, and what challenges remain. Sponsored By: Blue Matter, strategic consultants in the life sciences A look ahead at how cell-based therapies in oncology will advance during 2021-22: research, regulatory, and commercial milestones. Sponsored By: Baxter BioPharma Solutions While service directories are filled with CMOs claiming vaccine fill-finish experience, the logistical challenges resulting from seasonal product are unique and it is important that outsourcing partners can ensure quality and on-time delivery. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored By: Within3 We enable virtual work — offering over-time sessions where participants are more focused, insights are more diverse and business goals are met. Sponsored by: Catalent Discover the current state of patient-focused dose design through clinical evidence, real-world case studies and patient preference-driven drug design solutions that can help develop better treatments and successful real-world outcomes. Sponsored by: Catalent This eBook features insights from experts in the industry on patient-centric drug development challenges and strategies on advancing drug design and development effectively. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent In this webinar, pharmaceutical scientists present real-life examples of challenges they’ve overcome in the transfer of oral small molecules from a dedicated early-phase development site to a dedicated late-phase manufacturing site. | 
